Ascletis first to file biotech IPO under new HK regime
China's Ascletis Pharma has emerged as the first biotechnology firm to test the waters of Hong Kong’s new listing regime, after filing a draft prospectus on Monday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: